Chemomab is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need.

The company’s lead candidate, CM-101, is a first-in-class monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action.

Chemomab is currently promoting in parallel three phase 2 studies, focusing on the rare indications primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Recent News
Nov 16, 2023

--Systemic Sclerosis (SSc) Patient Data Shows High Serum CCL24 Levels Associated with More Severe Manifestations of Disease, Including Pulmonary Arterial Hypertension -- -- Study Reveals that...

Nov 15, 2023

—CM-101's Unique Dual Anti-Fibrotic and Anti-Inflammatory Activity Has Disease Modifying Potential in this Poorly Treated Condition— —CM-101's Phase 2 SPRING Trial in PSC is Advancing...

Nov 13, 2023

—New Proteomic Analyses of Phase 2a Liver Fibrosis Clinical Data Show Consistent and Significant Improvements in Liver-related Pathology Pathways After Treatment with CM-101— —Oral...

Nov 9, 2023

—Continued Strong Progress in Advancing CM-101 Phase 2 PSC Trial Towards Completion of Enrollment--On Track for Topline Readout in Second Half of 2024— —Reiterates Guidance that Cash...

All News

Stock Info
Tuesday, November 14, 2023
9:00am - 11:00am PST

Date: Nov. 14, 2023
Time: 9:00-11:00 am PT
Format: Poster presentation: The Involvement of CCR3-CCL24 Axis in Endothelial to Mesenchymal Transition Process and Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
Presenter: Ilan Vaknin, PhD, Vice President of R&D, Chemomab Therapeutics
Authors: Itzchak Amoyal, Tzipi Hornik-Lurie, Tali Zitman-Gal, Hilit Levy, Ilan Vaknin Liat Drucker, Ishai Heusler, Yair Levy, Shelly Tartakover Matalo
Session: Poster Session C, Systemic Sclerosis & Related Disorders – Clinical Poster III: Translational Science
Information: rheumatology.org/annual-meeting

Monday, November 13, 2023
4:30pm EST

Date: Nov. 13, 2023
Time: 4:30pm ET
Format: Oral presentation: Serum proteomics reveals unique association of CCL24 with disease-related pathways and signatures in primary sclerosing cholangitis
Presenter: Ilan Vaknin, PhD, Vice President of R&D, Chemomab Therapeutics, Ltd.
Authors: Tom Snir, Raanan Greenman, Revital Aricha, John Lawler, Francesca Saffioti, Douglas Thorburn, Massimo Pinzani, Adi Mor, Ilan Vaknin
Session: Room 312 - Breaking the Chains of Cholestatic Liver Injury: Advancements and Promising Treatment Strategies
Information: The Liver Meeting | AASLD

All Events

Featured Presentations


Chemomab Corporate Overview - November 2023


Annual Report


Chemomab 2022 Annual Report